Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
S, e incluso particularmente interesante
Other adverse reactions are rare, such as pancreatitis and rash
``` Varad_Patil January 30, 2025, 12:16pm 24 OneSource Q3FY25 Concall Snippets: Biologics: MSA is pre-approval and CSA is commercial (20-80 share in steady state will reach in medium term) Currently, all Biologics division revenue is from MSA (pre-approved molecules) Currently have 20 customers in GLP-1 space and OneSource is the primary supplier of GLP-1 cartridges for all the 20 customers Medium-term Guidance: Revenue growth of 25-30% CAGR with 40% EBITDA Margin over the next 5 years primarily driven by commercial contracts including GLP-1 Est
Ascendis would receive up to USD 285 million in payments
JAMA 2023;330:2000-15
Injectable GLP-1 medications are peptide-based drugs administered via subcutaneous injection, bypassing the gastrointestinal tract for absorption
US$ 23.17
US$ 22.17
US$ 25.58
